Trial Profile
A Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Cinryze (C1 Esterase Inhibitor [Human]) for the Treatment of Acute Antibody-mediated Rejection in Kidney Transplant Patients
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Complement C1 inhibitor protein (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Sponsors Shire; Takeda
- 06 Jun 2019 Status changed from active, no longer recruiting to discontinued.
- 30 May 2019 The study is discontinued in spain according to European Clinical Trials Database record.
- 15 May 2019 Status changed from recruiting to active, no longer recruiting.